## **FORM 11**

# NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: <u>Liberty Health Sciences Inc.</u>	(the "Issuer").
Trading Symbol: <u>LHS</u>	
Date: October 20, 2017	

## 1. New Options Granted:

Date of Grant: October 20, 2017

Name of Optionee	Position Employee/ Consultant/ Management Company	No. of Optioned Shares	Exercise Price	Expiry Date
Mike Galloro (Duck Capital Inc.)	Director	100,000	\$1.07	Oct.20,2022
Talal Rshaida	Operations & Processing Specialist Corporate	75,000	\$1.07	Oct.20,2022
Thomas Adams	Director of Financial Reporting Corporate	20,000	\$1.07	Oct.20,2022
Sherry Gartino	Director of Dispensary Operations Florida	20,000	\$1.07	Oct.20,2022
Fritz Myers	Production Manager Florida	20,000	\$1.07	Oct.20,2022
Beth Brown	Director of Patient Care Florida	20,000	\$1.07	Oct.20,2022
Laurinda Lee	Office Manager Corporate	7,500	\$1.07	Oct.20,2022
Cory Cacciavillani	Special Projects Florida	20,000	\$1.07	Oct.20,2022
Matt Booth	Director of Lab and Processing Florida	20,000	\$1.07	Oct.20,2022
Alicia Mahoney	Office Manager Florida	7,500	\$1.07	Oct.20,2022
TBD	Director of Cultivation Corporate	50,000	\$1.07	Oct.20,2022
TBD	General Manager Florida	50,000	\$1.07	Oct.20,2022
TBD	Director of Pharmacy Ohio	20,000	\$1.07	Oct.20,2022
TBD	Director of Operations Ohio	20,000	\$1.07	Oct.20,2022
General Pool	Discretion of the CEO (to eligible Optionees)	50,000	\$1.07	Oct.20,2022
Plants Not Pills	Consultant - Doctor Aggregator in Florida – performance based	2,000,000	\$1.07	Oct.20,2022
Echo Point	Consultant - Doctor Aggregator in Florida – performance based	500,000	\$1.07	Oct.20,2022

Total Number of optioned shares proposed for acceptance: 3,000,000.

### 2. Other Presently Outstanding Options:

	No. of Optioned	Exercise	Original Date	
Name of Optionee	Shares <sup>(1)</sup>	Price	of Grant	Expiry Date
Duck Capital Inc. (Michael Galloro)	100,000	\$1.20	February 17, 2017	July 20, 2018
Jonathan Leong	33,333	\$1.20	February 17, 2017	July 20, 2018
Peter Simeon	33,333	\$1.20	February 17, 2017	July 20, 2018
John O'Rourke	50,000	\$1.20	February 17, 2017	July 20, 2018
Roland Bopp	33,333	\$1.20	February 17, 2017	July 20, 2018
Arvin Ramos	6,667	\$2.85	March 29, 2016	July 20, 2018
Vic Neufeld	350,000	\$0.624	July 25, 2017	July 24, 2022
John Cervini	200,000	\$0.624	July 25, 2017	July 24, 2022
Aaron Serruya	100,000	\$0.624	July 25, 2017	July 24, 2022
George Scorsis	450,000	\$0.624	July 25, 2017	July 24, 2022
Rene Gulliver	300,000	\$0.624	July 25, 2017	July 24, 2022
Cole Cacciavillani	100,000	\$0.624	July 25, 2017	July 24, 2022

<sup>(1)</sup> Set out number of optioned shares for each grant with different terms.

#### 3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.
- (b) State the date of the news release announcing the grant of options.
- (c) State the total issued and outstanding share capital at the date of grant or amendment.
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

#### 4. Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated October 20, 2017

Rene Gulliver
Name of Director or Senior
Officer
(Signed) "Rene Gulliver"
Signature
Chief Financial Officer
Official Capacity